GlassScriptPhysician profile
Ingrid M Chacon
NPI 1275646515
$1,550.00
in general payments reported to CMS, 2019-2025
16 companies · $39.00 in 2025
The $39.00 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $39.56 · 2021: $90.63 · 2022: $291 · 2023: $612 · 2024: $242 · 2025: $39.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.11 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.16 | 2020-2024 | Rinvoq, Linzess, Viberzi |
| Madrigal Pharmaceuticals | $120.50 | 2024 | Rezdiffra |
| Merck Sharp & Dohme LLC | $114.24 | 2019 | |
| Janssen Biotech, INC. | $113.25 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Boston Scientific Corporation | $109.94 | 2019 | |
| Redhill Biopharma INC. | $109.40 | 2022-2024 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $92.98 | 2022-2023 | |
| Gilead Sciences, INC. | $47.16 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.45 | 2021 | |
| Olympus America INC. | $41.49 | 2020-2025 | Endoclot Phs |
| Mallinckrodt Hospital Products INC. | $30.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $29.21 | 2024-2025 | Voquezna |
| Pfizer INC. | $18.16 | 2023 | |
| Intercept Pharmaceuticals, INC. | $13.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Chacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.